← All trials
NCT05080218
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Oct 15, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 1000
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Foundation for Advancing Science Technology Education and ResearchLead sponsor
- AbbVieCollaborator
- Eli LillyCollaborator
- Foundation for Advancing Science Technology Education and ResearchOverall official - principal investigator
- Foundation for Advancing Science Technology Education and ResearchSponsor investigator
- Illumination HealthCollaborator
- PfizerCollaborator
- University of Alabama, BirminghamCollaborator
- University of NebraskaCollaborator
- University of PennsylvaniaCollaborator
- Bristol-Myers SquibbCollaborator
- Foundation for Advancing Science Technology Education and ResearchOfficial
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.